Losing pill against diabetes and overweight gives hope

Losing pill against diabetes and overweight gives hope

Grade
New active ingredient against diabetes and overweight gives hope








Researchers are working on a weight loss pill for diabetics and obese without side effects such as nausea or muscle loss. A study is promising, but there are open questions.

We have a pretty important problem. Almost half of the adult world population over 25 years is overweight or even obese. That is more than twice as many as it was 30 years ago. What has doubled in the course of this? The rate of people who suffer from diabetes. This is also why the hope that was associated with medication such as Wegovy and Ozempic was gigantic. In fact, the medication enables weight loss that other therapies can only dream of. Between ten and 15 percent can lose obese people well – at least as long as they keep injections. Patients with type 2 diabetes protect the funds from too strong fluctuations in blood sugar levels, and they also reduce the risk of complications.

And yet the medication does not come without side effects. Those who lose a lot of weight so quickly not only reduce their fat pads. 25 to 40 percent of the kilos lost by the weight loss injections are eliminated to break down fat -free mass, of which a considerable part of muscle mass. This is significantly more than with a conventional diet. In the worst case, such a muscle loss can lead to falling, broken bones and greater frailty.

The first phase is complete

There are also side effects such as nausea, vomiting, diarrhea or constipation, as well as a few rare but more serious complications. This is also a reason why more than half of the patients stop therapy in the first year. The world has long been working on alternatives in the world’s laboratories. One comes from Sweden from researchers from the Karolinska Institute and the University of Stockholm. The remedy is still in development, but has already completed the first phase of clinical studies. The

The tablet should lower the blood sugar level and increase fat burning – without negative effects on appetite or muscle mass. Because it has a completely different mechanism of action than, for example, Ozempic, which is injected under your skin every week.

diabetes
Ozempic weight loss injection in self -experiment: which unfortunately cannot be sprayed away

GLP-1 witnesses such as Ozempic influence the feeling of hunger through signals between the intestine and the brain. Instead, the new substance, which has been simply called ATR-258, activates the metabolism in the skeletal muscles instead by binding to a certain class of receptors. “ATR-258 Ahmt the effect of physical movement,” says Tore Bengtsson the star. Bengtsson is a professor at the Institute for Molecular Biosciences at the Wenner Gren Institute of the University of Stockholm and one of the researchers behind the study. “It selectively activates a signal path in the skeletal muscle, which promotes glucose intake and protein synthesis.”

Demolation pill leads to significant fat loss in animal experiments

In this way, the blood sugar can be reduced regardless of insulin. The problem is: If you activate these receptors in the entire body, there would be a dangerous increase in heart rate and probably also dangerous cardiac arrhythmias. Therefore, the researchers have developed a molecule that targeted the receptors in the muscles.

“In animal experiments, treatment has significantly improved blood sugar control and led to a significant fat loss while maintaining or increasing muscle mass,” reports Bengssson. Side effects associated with today’s GLP-1-based medication have not occurred.

Further studies must follow

In a small clinical phase 1 study with 48 healthy subjects and 25 people with type 2 diabetes, the treatment was also well tolerated. However, it can only be said whether it is hoped for in obese and people with diabetes with diabetes when many more patients have been examined. The next step for the scientists is therefore a larger clinical phase II study.

Only then does the phase III study follow. Patients who receive the treatment to be examined are usually compared with a control group that receives a different treatment. Only when all of these clinical phases have gone through will you know whether the remedy is really helping for people with obesity and diabetes.

However, the Stockholmers are not the only ones who work on an alternative to GLP 1 medication. Scientists presented another approach in the past year. Researchers at the University of Copenhagen described another active ingredient that could reduce appetite without loss of muscle mass or side effects such as nausea and vomiting. So far, however, the remedy has only been examined in the animal model.

Source: Stern

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest Posts